What is Leerink Partnrs’ Estimate for CGEM Q1 Earnings?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Cullinan Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($0.74) for the quarter. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. Leerink Partnrs also issued estimates for Cullinan Therapeutics’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.09.

Other research analysts have also recently issued reports about the company. UBS Group started coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $30.00 price target for the company. HC Wainwright lifted their price target on Cullinan Therapeutics from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $32.50.

Cullinan Therapeutics Trading Down 1.4 %

Shares of CGEM stock opened at $10.21 on Friday. The stock has a 50 day moving average of $11.42 and a 200 day moving average of $14.90. The stock has a market cap of $594.53 million, a P/E ratio of -3.60 and a beta of -0.16. Cullinan Therapeutics has a twelve month low of $9.50 and a twelve month high of $30.19.

Insider Activity

In other news, CEO Nadim Ahmed sold 8,400 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total value of $99,708.00. Following the sale, the chief executive officer now directly owns 263,150 shares of the company’s stock, valued at $3,123,590.50. The trade was a 3.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $12.51, for a total value of $50,040.00. Following the completion of the sale, the insider now directly owns 95,760 shares in the company, valued at $1,197,957.60. This represents a 4.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,582 shares of company stock worth $246,977 over the last three months. 6.07% of the stock is currently owned by corporate insiders.

Institutional Trading of Cullinan Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Cullinan Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 430,971 shares of the company’s stock worth $5,249,000 after acquiring an additional 7,012 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Cullinan Therapeutics by 32.9% in the fourth quarter. New York State Common Retirement Fund now owns 12,918 shares of the company’s stock worth $157,000 after acquiring an additional 3,200 shares during the last quarter. Rhumbline Advisers boosted its stake in Cullinan Therapeutics by 8.5% during the fourth quarter. Rhumbline Advisers now owns 68,208 shares of the company’s stock worth $831,000 after buying an additional 5,348 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Cullinan Therapeutics by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,346 shares of the company’s stock worth $150,000 after buying an additional 1,195 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Cullinan Therapeutics during the fourth quarter worth $136,000. 86.31% of the stock is owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.